Component
Serious glycemic adverse-event incidence
Serious glycemic adverse-event incidence. The model and exposure of each linked claim define its scope.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Niacin–laropiprant increased serious diabetes-control disturbances by 3.7 percentage points and new diabetes diagnoses by 1.3 points; gastrointestinal, musculoskeletal, skin, infection and bleeding serious adverse events also increased.
Experimental context and source evidence
- cross_nutrient
- Laropiprant / MK-0524 (coadministered_drug)
- evidence_span
- {"source_cache": "artifacts/niacin-clinical-sources/hps2014.abstract.txt", "locator": "Indexed primary abstract", "file_sha256": "9f12db5e258418187e65c3b921cffd01bf3cc0f400d3caa19cb4005c5e6f4f05", "start_char": 0, "end_char": 2717, "text_sha256": "9f12db5e258418187e65c3b921cffd01bf3cc0f400d3caa19cb4005c5e6f4f05"}
- experimental_model
- HPS2-THRIVE randomized trial; 25,673 adults with vascular disease on statin-based therapy
- exposure
- Extended-release nicotinic acid 2 g plus laropiprant 40 mg daily; median 3.9 years
- limitations
- Combination regimen; observed harm cannot all be assigned to nicotinic acid alone. Run-in selected participants able to tolerate initial therapy. Outcomes do not address deficiency replacement.
- nutrient_topic
- Niacin research collection; topical membership is not evidence of a direct dietary effect. · Niacin (vitamin B3)
- organism
- Homo sapiens
- plain_language
- The combination had measurable harms as well as lipid effects.
- primary_references
- [nia-clin-hps2014] Effects of extended-release niacin with laropiprant in high-risk patients. (2014). https://pubmed.ncbi.nlm.nih.gov/25014686/ DOI: 10.1056/nejmoa1300955
- tissue_or_cell_type
- Major vascular events and adverse events
Niacin: NAD metabolism, deficiency and nutrient interactions (2026-09-17) · lines 1417–1429
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · HPS2-THRIVE randomized trial; 25,673 adults with vascular disease on statin-based therapy · source_derived_draft · unverified_draft
### nia-clin-hps-glycemic-harm Niacin–laropiprant increased serious diabetes-control disturbances by 3.7 percentage points and new diabetes diagnoses by 1.3 points; gastrointestinal, musculoskeletal, skin, infection and bleeding serious adverse events also increased. Condition category: normal nutrient_topic: Niacin research collection; topical membership is not evidence of a direct dietary effect. plain_language: The combination had measurable harms as well as lipid effects. organism: Homo sapiens tissue_or_cell_type: Major vascular events and adverse events experimental_model: HPS2-THRIVE randomized trial; 25,673 adults with vascular disease on statin-based therapy limitations: Combination regimen; observed harm cannot all be assigned to nicotinic acid alone. Run-in selected participants able to tolerate initial therapy. Outcomes do not address deficiency replacement. exposure: Extended-release nicotinic acid 2 g plus laropiprant 40 mg daily; median 3.9 years cross_nutrient: Laropiprant / MK-0524 (coadministered_drug) evidence_span: {"source_cache": "artifacts/niacin-clinical-sources/hps2014.abstract.txt", "locator": "Indexed primary abstract", "file_sha256": "9f12db5e258418187e65c3b921cffd01bf3cc0f400d3caa19cb4005c5e6f4f05", "start_char": 0, "end_char": 2717, "text_sha256": "9f12db5e258418187e65c3b921cffd01bf3cc0f400d3caa19cb4005c5e6f4f05"} [nia-clin-hps2014] Effects of extended-release niacin with laropiprant in high-risk patients. (2014). https://pubmed.ncbi.nlm.nih.gov/25014686/ DOI: 10.1056/nejmoa1300955
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.